European Union leaders cranked up their criticism of the U.S. call to waive COVID-19 vaccine patents Saturday, arguing the move would yield no short-term or intermediate improvement in vaccine supplies and could even have a negative impact.
European Union leaders cranked up their criticism of the U.S. call to waive COVID-19 vaccine patents Saturday, arguing the move would yield no short-term or intermediate improvement in vaccine supplies and could even have a negative impact.
